Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy
Source check: Source checked. Not independent scientific confirmation.
Finding: Original full text, Methods/Results: autoencoder and SHAP feature selection on expression profiles yielded CLL therapy-need/time-to-first-treatment model; prospective observational cohort but model evaluation retrospective (217 analyzed); test AUC 0.91. Prognostic association, not prospective clinical utility. Methods/Results specify cohort, reference/outcome, split or experimental comparator and limitations.
Technology: Autoencoder and SHAP gene-selection workflow
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Uses expression-profile features selected with an autoencoder and SHAP to model CLL therapy need and time to first treatment.
- Test and result
- Original full text, Methods/Results: autoencoder and SHAP feature selection on expression profiles yielded CLL therapy-need/time-to-first-treatment model; prospective observational cohort but model evaluation retrospective (217 analyzed); test AUC 0.91. Prognostic association, not prospective clinical utility.
- Limitation / still unknown
- Methods/Results specify cohort, reference/outcome, split or experimental comparator and limitations. The source does not establish benefits beyond the reported evaluation.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1198992/full · https://europepmc.org/article/MED/37719021
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: other. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.